{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:59:45Z","timestamp":1790629185625,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010903","name":"National Science Foundation of China | Key Programme","doi-asserted-by":"publisher","award":["82403269"],"award-info":[{"award-number":["82403269"]}],"id":[{"id":"10.13039\/501100010903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M740931"],"award-info":[{"award-number":["2023M740931"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZC20233466"],"award-info":[{"award-number":["GZC20233466"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403269"],"award-info":[{"award-number":["82403269"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02671-y","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:30:13Z","timestamp":1779895813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["LISS enables immune evasion of colorectal cancers irrespective of MSI status"],"prefix":"10.1038","volume":"11","author":[{"given":"Qingyu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiying","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangwen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minqiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0342-9593","authenticated-orcid":false,"given":"Guixue","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanliang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Burenina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2469-5604","authenticated-orcid":false,"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2671_CR1","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Immune checkpoint therapy-current perspectives and future directions. Cell 186, 1652\u20131669 (2023).","journal-title":"Cell"},{"key":"2671_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-021-00569-4","volume":"19","author":"K Ganesh","year":"2022","unstructured":"Ganesh, K. Optimizing immunotherapy for colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 19, 93\u201394 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2671_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41571-024-00943-6","volume":"21","author":"CJM Williams","year":"2024","unstructured":"Williams, C. J. M. et al. Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response. Nat. Rev. Clin. Oncol. 21, 839\u2013851 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2671_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1126\/science.aau0447","volume":"364","author":"R Mandal","year":"2019","unstructured":"Mandal, R. et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science 364, 485\u2013491 (2019).","journal-title":"Science"},{"key":"2671_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.trecan.2017.01.004","volume":"3","author":"A L\u00f3pez-Soto","year":"2017","unstructured":"L\u00f3pez-Soto, A., Gonzalez, S. & Folgueras, A. R. IFN signaling and ICB resistance: time is on tumor\u2019s side. Trends Cancer 3, 161\u2013163 (2017).","journal-title":"Trends Cancer"},{"key":"2671_CR6","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips, R. L. et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell 185, 3857\u20133876 (2022).","journal-title":"Cell"},{"key":"2671_CR7","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"JE Darnell Jr.","year":"1994","unstructured":"Darnell, J. E. Jr., Kerr, I. M. & Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415\u20131421 (1994).","journal-title":"Science"},{"key":"2671_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ccell.2022.12.009","volume":"41","author":"MA Coelho","year":"2023","unstructured":"Coelho, M. A. et al. Base editing screens map mutations affecting interferon-\u03b3 signaling in cancer. Cancer Cell 41, 288\u2013303.e286 (2023).","journal-title":"Cancer Cell"},{"key":"2671_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25\u201339 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2671_CR10","first-page":"43","volume":"4","author":"J Qiu","year":"2023","unstructured":"Qiu, J. et al. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat. Cancer 4, 43\u201361 (2023).","journal-title":"Nat. Cancer"},{"key":"2671_CR11","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1016\/j.molcel.2022.05.027","volume":"82","author":"AB Herman","year":"2022","unstructured":"Herman, A. B., Tsitsipatis, D. & Gorospe, M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol. Cell 82, 2252\u20132266 (2022).","journal-title":"Mol. Cell"},{"key":"2671_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s43018-021-00196-7","volume":"2","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer. Nat. Cancer 2, 457\u2013473 (2021).","journal-title":"Nat. Cancer"},{"key":"2671_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41556-021-00672-3","volume":"23","author":"G Li","year":"2021","unstructured":"Li, G. et al. LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nat. Cell Biol. 23, 526\u2013537 (2021).","journal-title":"Nat. Cell Biol."},{"key":"2671_CR14","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s43018-022-00444-4","volume":"3","author":"F Shao","year":"2022","unstructured":"Shao, F. et al. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade. Nat. Cancer 3, 1192\u20131210 (2022).","journal-title":"Nat. Cancer"},{"key":"2671_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48\u201361 (2015).","journal-title":"Cell"},{"key":"2671_CR16","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013w514 (2020).","journal-title":"Nucleic Acids Res."},{"key":"2671_CR17","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","volume":"44","author":"JM Pitt","year":"2016","unstructured":"Pitt, J. M. et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44, 1255\u20131269 (2016).","journal-title":"Immunity"},{"key":"2671_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto, K. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 581, 100\u2013105 (2020).","journal-title":"Nature"},{"key":"2671_CR19","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","volume":"20","author":"FJ Barrat","year":"2019","unstructured":"Barrat, F. J., Crow, M. K. & Ivashkiv, L. B. Interferon target-gene expression and epigenomic signatures in health and disease. Nat. Immunol. 20, 1574\u20131583 (2019).","journal-title":"Nat. Immunol."},{"key":"2671_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0092-8674(95)90311-9","volume":"82","author":"Z Wen","year":"1995","unstructured":"Wen, Z., Zhong, Z. & Darnell, J. E. Jr Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82, 241\u2013250 (1995).","journal-title":"Cell"},{"key":"2671_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.tcb.2019.07.002","volume":"29","author":"N Curdy","year":"2019","unstructured":"Curdy, N., Lanvin, O., Laurent, C., Fourni\u00e9, J. J. & Franchini, D. M. Regulatory mechanisms of inhibitory immune checkpoint receptors expression. Trends Cell Biol. 29, 777\u2013790 (2019).","journal-title":"Trends Cell Biol."},{"key":"2671_CR22","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189\u20131201 (2017).","journal-title":"Cell Rep."},{"key":"2671_CR23","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/2159-8290.CD-20-0812","volume":"11","author":"SS Gu","year":"2021","unstructured":"Gu, S. S. et al. Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discov. 11, 1524\u20131541 (2021).","journal-title":"Cancer Discov."},{"key":"2671_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ccell.2024.02.013","volume":"42","author":"JD Beck","year":"2024","unstructured":"Beck, J. D. et al. Long-lasting mRNA-encoded interleukin-2 restores CD8(+) T cell neoantigen immunity in MHC class I-deficient cancers. Cancer Cell 42, 568\u2013582.e511 (2024).","journal-title":"Cancer Cell"},{"key":"2671_CR25","doi-asserted-by":"publisher","first-page":"6451","DOI":"10.1016\/j.cell.2024.10.024","volume":"187","author":"LL Chen","year":"2024","unstructured":"Chen, L. L. & Kim, V. N. Small and long non-coding RNAs: past, present, and future. Cell 187, 6451\u20136485 (2024).","journal-title":"Cell"},{"key":"2671_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/ni1548","volume":"9","author":"L Wang","year":"2008","unstructured":"Wang, L. et al. \u2018Tuning\u2019 of type I interferon-induced Jak-STAT1 signaling by calcium-dependent kinases in macrophages. Nat. Immunol. 9, 186\u2013193 (2008).","journal-title":"Nat. Immunol."},{"key":"2671_CR27","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.cell.2022.04.028","volume":"185","author":"N Alphonse","year":"2022","unstructured":"Alphonse, N. et al. A family of conserved bacterial virulence factors dampens interferon responses by blocking calcium signaling. Cell 185, 2354\u20132369.e2317 (2022).","journal-title":"Cell"},{"key":"2671_CR28","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1158\/0008-5472.CAN-07-2509","volume":"68","author":"J Si","year":"2008","unstructured":"Si, J. & Collins, S. J. Activated Ca2+\/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. Cancer Res. 68, 3733\u20133742 (2008).","journal-title":"Cancer Res."},{"key":"2671_CR29","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1093\/nar\/gkg599","volume":"31","author":"IL Hofacker","year":"2003","unstructured":"Hofacker, I. L. Vienna RNA secondary structure server. Nucleic Acids Res. 31, 3429\u20133431 (2003).","journal-title":"Nucleic Acids Res."},{"key":"2671_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","volume":"34","author":"SH Baumeister","year":"2016","unstructured":"Baumeister, S. H., Freeman, G. J., Dranoff, G. & Sharpe, A. H. Coinhibitory pathways in immunotherapy for cancer. Annu. Rev. Immunol. 34, 539\u2013573 (2016).","journal-title":"Annu. Rev. Immunol."},{"key":"2671_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57046-8","volume":"16","author":"X Yang","year":"2025","unstructured":"Yang, X. et al. Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancer. Nat. Commun. 16, 1871 (2025).","journal-title":"Nat. Commun."},{"key":"2671_CR32","doi-asserted-by":"publisher","first-page":"D46","DOI":"10.1093\/nar\/gkac1067","volume":"51","author":"J Huang","year":"2023","unstructured":"Huang, J. et al. ChIPBase v3.0: the encyclopedia of transcriptional regulations of non-coding RNAs and protein-coding genes. Nucleic Acids Res. 51, D46\u2013d56 (2023).","journal-title":"Nucleic Acids Res."},{"key":"2671_CR33","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1158\/2159-8290.CD-20-1571","volume":"11","author":"W Du","year":"2021","unstructured":"Du, W. et al. Loss of optineurin drives cancer immune evasion via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation. Cancer Discov. 11, 1826\u20131843 (2021).","journal-title":"Cancer Discov."},{"key":"2671_CR34","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41586-023-06721-1","volume":"623","author":"A Malik","year":"2023","unstructured":"Malik, A. et al. Epithelial IFN\u03b3 signalling and compartmentalized antigen presentation orchestrate gut immunity. Nature 623, 1044\u20131052 (2023).","journal-title":"Nature"},{"key":"2671_CR35","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.omtn.2020.01.018","volume":"19","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. Efficient delivery of antisense oligonucleotides using bioreducible lipid nanoparticles in vitro and in vivo. Mol. Ther. Nucleic Acids 19, 1357\u20131367 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2671_CR36","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.ccell.2024.06.009","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell 42, 1268\u20131285.e1267 (2024).","journal-title":"Cancer Cell"},{"key":"2671_CR37","volume":"2","author":"I Rauch","year":"2013","unstructured":"Rauch, I., M\u00fcller, M. & Decker, T. The regulation of inflammation by interferons and their STATs. JAKSTAT 2, e23820 (2013).","journal-title":"JAKSTAT"},{"key":"2671_CR38","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798\u2013809 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"2671_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher, A. M., Workman, C. J. & Vignali, D. A. A. Interferon-\u03b3: teammate or opponent in the tumour microenvironment?. Nat. Rev. Immunol. 22, 158\u2013172 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2671_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle, M., El-Daly, S. M., Fabbri, M. & Calin, G. A. Noncoding RNA therapeutics - challenges and potential solutions. Nat. Rev. Drug Discov. 20, 629\u2013651 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2671_CR41","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/s41592-022-01623-y","volume":"19","author":"J Zhang","year":"2022","unstructured":"Zhang, J., Fei, Y., Sun, L. & Zhang, Q. C. Advances and opportunities in RNA structure experimental determination and computational modeling. Nat. Methods 19, 1193\u20131207 (2022).","journal-title":"Nat. Methods"},{"key":"2671_CR42","doi-asserted-by":"publisher","first-page":"116351","DOI":"10.1016\/j.celrep.2025.116351","volume":"44","author":"J Hu","year":"2025","unstructured":"Hu, J. et al. CD169(+) macrophages identify and eliminate tumor cells in colorectal cancer through CD169\/CD43 interaction and FasL-driven apoptosis. Cell Rep. 44, 116351 (2025).","journal-title":"Cell Rep."},{"key":"2671_CR43","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.cell.2019.01.036","volume":"176","author":"T Fu","year":"2019","unstructured":"Fu, T. et al. FXR regulates intestinal cancer stem cell proliferation. Cell 176, 1098\u20131112.e1018 (2019).","journal-title":"Cell"},{"key":"2671_CR44","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim, S. O. et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer cell 30, 925\u2013939 (2016).","journal-title":"Cancer cell"},{"key":"2671_CR45","doi-asserted-by":"crossref","unstructured":"Revenko, A. et al. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer. J. Immunother. Cancer 10 e003892 (2022).","DOI":"10.1136\/jitc-2021-003892"},{"key":"2671_CR46","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022112408","volume":"42","author":"J Yi","year":"2023","unstructured":"Yi, J. et al. CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS. EMBO J. 42, e112408 (2023).","journal-title":"EMBO J."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02671-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02671-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02671-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:02:18Z","timestamp":1779901338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02671-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2671"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02671-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}